Since the results of the Javelin 100 bladder trial, avelumab (anti-PDL1) as a maintenance treatment has become part of the treatment armamentarium for urothelial carcinoma, with an important impact on overall survival upon response to first-line palliative chemotherapy [6]. The gene discussed is CD274; the disease is urothelial carcinoma.